Mauli Verma, MD
Psychiatry · Kalamazoo, MINPI 1134322308
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,561 of the $2,615 with a category attached, or 97.9%. Brainsway USA Inc accounts for 97.9% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $2,573 and has fallen 99.4% since, to $14 in 2025.
Across 4 payments — averaging $653.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Brainsway USA Inc$3K
- Lundbeck LLC$27
- Vanda Pharmaceuticals Inc.$14
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$13
Across 74 payments — averaging $788.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$56K
- H. Lundbeck A S$3K
What the payments were for
- Speaking & faculty fees$2,56198%
- Food & beverage$271%
- Education$271%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Brainsway USA Inc | 1 | $2,561 |
| Lundbeck LLC | 1 | $27 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Brainsway Deep TMS$2,561
How this compares
$2,615 in reported general payments places this provider in the 85th percentile of 1,166 psychiatry providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 16 | $1,161 |
| Quetiapine Fumarate | 91 | $1,066 |
| Sertraline Hcl | 63 | $696 |
| Lamotrigine | 43 | $688 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 41 | $652 |
| RivastigmineRivastigmine Tartrate | 18 | $634 |
| Mirtazapine | 27 | $589 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 18 | $563 |
| Duloxetine Hcl | 31 | $414 |
| Fluoxetine Hcl | 13 | $396 |
| Escitalopram Oxalate | 23 | $351 |
| Paroxetine Hcl | 14 | $318 |
| Lithium Carbonate ErLithium Carbonate | 27 | $248 |
| Memantine Hcl | 13 | $203 |
| Risperidone | 19 | $144 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Kalamazoo
- Rajiv TandonKalamazoo$45K
- Aries SternKalamazoo$35K
- Nilanjan GajareKalamazoo$22K
- Andreas SidiropoulasDetroit$2.8M
- Welton WashingtonYpsilanti$1.4M
- Joel YoungRochester Hills$1.1M
- Manzar RajputMonroe$612K
- William GuySouthfield$562K
- Robert LagrouClarkston$267K
- Michael IngramBay City$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.